Blueprint Medicines Corporation (NASDAQ:BPMC) insider Marion Dorsch sold 18,334 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the sale, the insider now directly owns 18,334 shares of the company’s stock, valued at approximately $1,199,960.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Blueprint Medicines Corporation (NASDAQ BPMC) traded up $4.56 on Wednesday, hitting $70.36. 324,318 shares of the company were exchanged, compared to its average volume of 430,033. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $74.42.

Blueprint Medicines Corporation (NASDAQ:BPMC) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.06). Blueprint Medicines Corporation had a negative net margin of 437.83% and a negative return on equity of 43.11%. The firm had revenue of $8.07 million for the quarter, compared to analysts’ expectations of $5.35 million. During the same quarter last year, the firm posted ($0.62) EPS. The firm’s quarterly revenue was up 31.0% compared to the same quarter last year. equities analysts expect that Blueprint Medicines Corporation will post -3.74 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Blueprint Medicines Corporation (BPMC) Insider Marion Dorsch Sells 18,334 Shares” was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/blueprint-medicines-corporation-bpmc-insider-marion-dorsch-sells-18334-shares/1720451.html.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Canaccord Genuity set a $56.00 price objective on shares of Blueprint Medicines Corporation and gave the company a “buy” rating in a research report on Wednesday, August 2nd. BidaskClub downgraded shares of Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 19th. Wedbush restated an “outperform” rating and set a $66.00 target price on shares of Blueprint Medicines Corporation in a research note on Tuesday, August 22nd. Finally, DA Davidson started coverage on shares of Blueprint Medicines Corporation in a research note on Friday, September 29th. They set a “buy” rating and a $90.00 target price on the stock. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $70.47.

Hedge funds have recently made changes to their positions in the business. Rockefeller Financial Services Inc. purchased a new stake in Blueprint Medicines Corporation in the 3rd quarter worth $160,000. Turner Investments LLC purchased a new stake in Blueprint Medicines Corporation in the 3rd quarter worth $209,000. Great West Life Assurance Co. Can lifted its stake in Blueprint Medicines Corporation by 53.6% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,163 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Blueprint Medicines Corporation by 68.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,391 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Blueprint Medicines Corporation in the 3rd quarter worth $244,000. Institutional investors and hedge funds own 91.99% of the company’s stock.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.